HomeCompareNAOV vs ORCC

NAOV vs ORCC: Dividend Comparison 2026

NAOV yields 105.26% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NAOV wins by $4.80M in total portfolio value
10 years
NAOV
NAOV
● Live price
105.26%
Share price
$1.90
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.82M
Annual income
$1,680,113.32
Full NAOV calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — NAOV vs ORCC

📍 NAOV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNAOVORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NAOV + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NAOV pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NAOV
Annual income on $10K today (after 15% tax)
$8,947.37/yr
After 10yr DRIP, annual income (after tax)
$1,428,096.32/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, NAOV beats the other by $1,428,095.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NAOV + ORCC for your $10,000?

NAOV: 50%ORCC: 50%
100% ORCC50/50100% NAOV
Portfolio after 10yr
$2.42M
Annual income
$840,057.18/yr
Blended yield
34.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

NAOV
No analyst data
Altman Z
-2.3
Piotroski
0/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NAOV buys
0
ORCC buys
0
No recent congressional trades found for NAOV or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNAOVORCC
Forward yield105.26%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$4.82M$21.4K
Annual income after 10y$1,680,113.32$1.04
Total dividends collected$4.33M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: NAOV vs ORCC ($10,000, DRIP)

YearNAOV PortfolioNAOV Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$21,226$10,526.32$11,190$489.61+$10.0KNAOV
2$43,594$20,881.77$12,229$256.01+$31.4KNAOV
3$86,726$40,080.65$13,216$130.74+$73.5KNAOV
4$167,317$74,520.40$14,207$66.02+$153.1KNAOV
5$313,393$134,363.82$15,234$33.17+$298.2KNAOV
6$570,536$235,205.45$16,317$16.62+$554.2KNAOV
7$1,010,656$400,181.57$17,468$8.32+$993.2KNAOV
8$1,743,912$662,511.02$18,695$4.16+$1.73MNAOV
9$2,934,379$1,068,392.54$20,006$2.08+$2.91MNAOV
10$4,819,899$1,680,113.32$21,407$1.04+$4.80MNAOV

NAOV vs ORCC: Complete Analysis 2026

NAOVStock

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.

Full NAOV Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this NAOV vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NAOV vs SCHDNAOV vs JEPINAOV vs ONAOV vs KONAOV vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.